Drug intelligence / Profile preview

Blue-T

Development stage: Preclinical
Lead developer: ITL Pharma

Overview

Blue-T is an investigational diagnostic agent being developed by ITL Pharma. It is primarily targeted toward the early detection and diagnosis of ductal carcinoma and systemic infections. While it is a key component of ITL Pharma's diagnostic pipeline, specific details regarding its chemical structure, molecular targets, and precise mechanism of action remain proprietary and have not been extensively detailed in public clinical literature. The agent is intended to improve diagnostic accuracy in oncology and infectious disease settings.

Beyond the preview

Go deeper on Blue-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue-T.

Explore the full profile